Showing 6571-6580 of 6770 results for "".
- Strathspey Crown Hosts Founders Summithttps://practicaldermatology.com/news/20121002-strathspey_crown_hosts_founders_summit/2459717/Strathspey Crown recently hosted its Founders Summit & Retreat at Pelican Hill in Newport Beach, CA. The event gathered approximately 50 of the top physicians from elective healthcare and national leaders from government, healthcare, and f
- Stiefel/GSK Receives FDA Approval of Sorilux Foam, 0.005%https://practicaldermatology.com/news/20121002-stiefel_receives_fda_approval_of_sorilux_foam_0005/2459719/The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005% from Stiefel/GSK. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psor
- Janssen to Develop, Commercialize JAK Inhibitor For Immunological Diseaseshttps://practicaldermatology.com/news/20121002-janssen_to_develop_commercialize_jak_inhibitor_for_immunological_diseases/2459720/Janssen Biotech, Inc. entered into a license agreement with Astellas Pharma Inc. for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for mod
- Syneron Kicks Off New Campaignhttps://practicaldermatology.com/news/20121002-syneron_kicks_off_new_campaign/2459721/Syneron Medical Ltd. launched a new Break Up. Get Even! campaign for its elure product line. As part of the campaign, five winners will receive a complete elure range of products ($335 value) to “break up” stubborn discoloration and “get even” skin tone. The campaign is run through the company's
- Provectus Pharmaceuticals Publishes Patent Application, PV-10 Resultshttps://practicaldermatology.com/news/20121002-provectus_pharmaceuticals_publishes_patent_application/2459722/Provectus Pharmaceuticals, Inc. announced that a patent application has been published for US and international patents covering the combination of local and systemic immunomodulative therapies for cancer treatment. The patent, entitled "Combination
- Lucid, Inc. Now Named Caliber IDhttps://practicaldermatology.com/news/20120926-lucid_inc_now_named_caliber_id/2459729/Lucid, Inc. announced that it is now operating under a new company name, Caliber Imaging & Diagnostics, Inc., or Caliber ID. Caliber ID has created an entirely new class of tools enabling physicians to image and diagnose skin disease in real tim
- New Practice Offers Personalized Procedureshttps://practicaldermatology.com/news/20120926-new_practice_offers_personalized_procedures/2459730/Dermatologist Candace Thornton Spann, MD, FAAD, and plastic surgeon Marvin Spann, MD, established a joint practice, Couture Dermatology & Plastic Surgery. The practice, which opens October 1, will offer custom-tailored treatments for all et
- New Survey: Rosacea Inflicts Physical Discomforthttps://practicaldermatology.com/news/20120925-new_survey_rosacea_inflicts_physical_discomfort/2459731/A recent survey conducted by the National Rosacea Society (NRS) shows that significant physical discomfort often accompanies the visible signs of rosacea. In the survey of 1,709 patients with rosacea, nearly 93 percent said they had experienced physical discomfort as a result of the disorder. A burn
- Physicians Report Health IT Growing But Systems Laghttps://practicaldermatology.com/news/20120921-physicians_report_health_it_growing_but_systems_lag/2459732/A new Optum Institute/Harris Interactive national survey provides insights into US consumers' willingness to view their medical records and engage with care providers online. The survey was conducted online within the United States among 1,000 US physicians, 2,870 US adults, and 400 US hospital exec
- Provectus Pharmaceuticals to Present Data on PV-10https://practicaldermatology.com/news/20120918-provectus_pharmaceuticals_to_present_data_on_pv-10/2459733/Provectus Pharmaceuticals, Inc. announced that final efficacy data from its Phase II trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival and overall survival),